Insulet Co. (NASDAQ:PODD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Insulet Co. (NASDAQ:PODD) has been given a consensus recommendation of “Moderate Buy” by the sixteen research firms that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $272.81.

Several equities research analysts recently commented on PODD shares. Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target for the company. Canaccord Genuity Group upped their target price on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. TD Cowen lifted their price target on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Raymond James upped their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Finally, BTIG Research lifted their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th.

Insulet Stock Up 1.1 %

Shares of NASDAQ PODD opened at $275.81 on Monday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a 50-day moving average of $266.30 and a 200 day moving average of $232.96. Insulet has a 12-month low of $160.19 and a 12-month high of $279.77. The stock has a market cap of $19.35 billion, a PE ratio of 47.23, a P/E/G ratio of 3.41 and a beta of 1.22.

Insider Activity at Insulet

In other news, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.47% of the company’s stock.

Institutional Investors Weigh In On Insulet

Hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new position in Insulet in the second quarter valued at $99,978,000. Baillie Gifford & Co. increased its position in Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after acquiring an additional 389,639 shares during the period. Mizuho Securities USA LLC increased its holdings in shares of Insulet by 5,928.1% in the third quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after purchasing an additional 320,416 shares during the period. Charles Schwab Investment Management Inc. raised its position in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after buying an additional 193,839 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.